Objective To evaluate the efficacy and safety of the paclitaxelcontaining chemotherapy regimens as the firstline treatment for advanced gastric cancer. Methods In this retrospective analysis，379 patients with advanced gastric cancer were divided into four groups based on their chemotherapy regimens：group A（paclitaxel+oxaliplatin+calcium folinate+fluorouracil，n=95），group B（paclitaxel+calcium folinate+fluorouracil，n=167）， group C（paclitaxel+oxaliplatin，n=94） and group D（paclitaxel alone，n=23）.The response rate（RR）， disease control rate（DCR）， progressionfree survival（PFS） and overall survival（OS） as well as toxicity during treatment were investigated among four groups. Results The RR and DCR of group A， B， C and D were 47.3％ and 89.2％，52.1％ and 92.6％，60.0％ and 89.5％， 39.1％ and 69.％，respectively. Meanwhile，the median OS and PFS were 11.4 and 6.6 months， 11.7 and 7.2 months，11.7 and 7.2 months，7.5 and 4.1 months, respectively. The incidence of grade 3-4 toxicities were lower than 20.0％ among four groups despite the grade 3-4 leukopenia with the incidence more than 25.0％. The grade 3-4 nause/vomitting, fatigue and leukopenia in group A were higher than those in other 3 groups（P＜0.05）. Conclusion The paclitaxelcontaining chemotherapy regimens can be the firstline chemotherapy regimens for the advanced gastric cancer.